Published in JAMA on July 01, 1998
Estimation of HIV incidence in the United States. JAMA (2008) 21.27
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health (2001) 6.29
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. Am J Public Health (2001) 5.32
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health (2001) 3.27
Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med (2006) 3.09
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol (2004) 2.94
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health (2005) 2.62
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect (2006) 2.45
Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One (2012) 2.41
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health (2004) 2.27
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Monitoring the incidence of HIV infection in the United States. Public Health Rep (2007) 2.21
Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol (2006) 2.19
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics. Sex Transm Infect (2006) 2.17
Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol (2002) 2.11
Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol (2010) 2.07
Relating recent infection prevalence to incidence with a sub-population of assay non-progressors. J Math Biol (2009) 2.06
Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. AIDS Behav (2009) 2.03
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A (2001) 2.02
The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department. J Acquir Immune Defic Syndr (2008) 1.94
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A (2001) 1.94
Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. J HIV AIDS Surveill Epidemiol (2010) 1.90
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One (2010) 1.83
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Recent trends in HIV and other STIs in the United Kingdom: data to the end of 2002. Sex Transm Infect (2004) 1.79
Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. PLoS Med (2013) 1.78
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol (2005) 1.77
More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med (2011) 1.74
Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect (2010) 1.67
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol (2001) 1.65
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health (2008) 1.61
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57
Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One (2011) 1.56
A new general biomarker-based incidence estimator. Epidemiology (2012) 1.55
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
High HIV and ulcerative sexually transmitted infection incidence estimates among men who have sex with men in Peru: awaiting for an effective preventive intervention. J Acquir Immune Defic Syndr (2009) 1.51
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47
Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 1.47
Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis (2009) 1.46
Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol (2001) 1.46
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill (2010) 1.45
Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002. J Acquir Immune Defic Syndr (2005) 1.43
Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol (2013) 1.43
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis (2012) 1.43
A comparison of biomarker based incidence estimators. PLoS One (2009) 1.41
HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS (2010) 1.41
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One (2010) 1.39
Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One (2013) 1.35
Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol (2005) 1.35
Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr (2009) 1.34
Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med (2007) 1.33
Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr (2013) 1.31
Identification of primary HIV-1C infection in Botswana. AIDS Care (2008) 1.29
Using HIV networks to inform real time prevention interventions. PLoS One (2014) 1.29
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS (2012) 1.29
Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol (2008) 1.28
Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr (2009) 1.27
Interpopulation variation in HIV testing promptness may introduce bias in HIV incidence estimates using the serologic testing algorithm for recent HIV seroconversion. Sex Transm Infect (2010) 1.27
Loss of T cell responses following long-term cryopreservation. J Immunol Methods (2007) 1.23
Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: a hard hit area along a major drug trafficking route. BMC Public Health (2010) 1.23
Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev (2007) 1.23
On the use of adjusted cross-sectional estimators of HIV incidence. J Acquir Immune Defic Syndr (2009) 1.22
Estimating the HIV incidence rate: recent and future developments. Curr Opin HIV AIDS (2011) 1.21
Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One (2011) 1.20
Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J Clin Microbiol (2005) 1.20
Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation. J Clin Microbiol (2012) 1.18
Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health (2001) 1.17
Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS (2011) 1.16
Estimating HIV incidence based on combined prevalence testing. Biometrics (2009) 1.15
Does the recent increase in HIV diagnoses among men who have sex with men in the UK reflect a rise in HIV incidence or increased uptake of HIV testing? Sex Transm Infect (2006) 1.15
Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial (ANRS-1265). BMC Infect Dis (2010) 1.15
Targeted testing for acute HIV infection in North Carolina. AIDS (2009) 1.14
Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods. Stat Med (2010) 1.12
Prevalence and correlates of unknown HIV infection among patients seeking care in a public hospital emergency department. Public Health Rep (2009) 1.10
Stochastic models to demonstrate the effect of motivated testing on HIV incidence estimates using the serological testing algorithm for recent HIV seroconversion (STARHS). Sex Transm Infect (2010) 1.10
Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One (2011) 1.09
Decline in HIV prevalence among young women in Zambia: national-level estimates of trends mask geographical and socio-demographic differences. PLoS One (2012) 1.08
Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol (2008) 1.06
Seroincidence of recent human immunodeficiency virus type 1 infections in China. Clin Vaccine Immunol (2007) 1.06
Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One (2012) 1.05
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Socioeconomic status and health. The challenge of the gradient. Am Psychol (1994) 13.59
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med (1996) 7.28
Socioeconomic inequalities in health. No easy solution. JAMA (1993) 7.11
Large community outbreak of cryptosporidiosis due to contamination of a filtered public water supply. N Engl J Med (1989) 6.22
Seroprevalence of human immunodeficiency virus among childbearing women. Estimation by testing samples of blood from newborns. N Engl J Med (1988) 6.00
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med (1998) 3.81
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Probability of female-to-male transmission of HIV-1 in Thailand. Lancet (1994) 3.66
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med (1995) 3.33
Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion (2002) 3.24
HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group. N Engl J Med (1992) 3.01
Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA (1993) 2.93
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med (1995) 2.63
Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion (1995) 2.60
Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation. Biometrics (2001) 2.57
Protease inhibitors in the homeless. JAMA (1997) 2.57
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang (2005) 2.47
Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med (2001) 2.39
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA (1998) 2.36
Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.35
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
Preventive health care for adults with HIV infection. JAMA (1993) 2.29
Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr (1999) 2.28
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
How do medical residents discuss resuscitation with patients? J Gen Intern Med (1995) 2.20
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 2.20
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med (1993) 2.14
Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet (1997) 2.12
Improving on a coin toss to predict patient adherence to medications. Ann Intern Med (2001) 2.06
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother (1998) 1.94
Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group. Ann Intern Med (1999) 1.94
Adherence: a necessity for successful HIV combination therapy. AIDS (1999) 1.91
Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.88
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect (2001) 1.85
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses (2001) 1.81
Questionable efficacy of confidential unit exclusion. Transfusion (1990) 1.81
Prevention of heterosexual transmission of human immunodeficiency virus through couple counseling. J Acquir Immune Defic Syndr (1993) 1.79
Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion (1994) 1.78
The consequences of a positive prenatal HIV antibody test for women. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.74
Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med (1997) 1.71
Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS (2001) 1.70
Nonparametric estimation for the three-stage irreversible illness-death model. Biometrics (2000) 1.70
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
In vitro evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection. J Infect Dis (2008) 1.67
Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol (2000) 1.64
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol (1997) 1.63
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood (1999) 1.59
A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis (1998) 1.57
A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc Natl Acad Sci U S A (2000) 1.55
Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med (1996) 1.55
Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med (1997) 1.52
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol (1995) 1.50
See one, do one, teach one? House staff experience discussing do-not-resuscitate orders. Arch Intern Med (1996) 1.50
Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. Eur J Heart Fail (2015) 1.49
Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion (2003) 1.47
Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion (2001) 1.46
Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol (2001) 1.46
Primary HIV infection--a public health opportunity. Am J Public Health (1997) 1.44
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion (2001) 1.43
Does HIV reporting by name deter testing? MESH Study Group. AIDS (2000) 1.43
Can a back pain screening tool help classify patients with acute pain into risk levels for chronic pain? Eur J Pain (2015) 1.42
Transfusion-transmitted arboviruses. Vox Sang (2009) 1.42
HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996. STD Clinic HIV Seroincidence Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.41
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion (2003) 1.41
HHV-6 infection in patients with HIV-1 infection and disease. AIDS Read (2003) 1.40
Risk factors for postcoital bleeding among women with or at risk for infection with human immunodeficiency virus. J Infect Dis (1995) 1.40
Scintigraphic evaluation of digital circulation during the developmental and acute phases of equine laminitis. Equine Vet J (1990) 1.39
Determination of T-lymphocyte subsets on site in rural Tanzania: results in HIV-1 infected and non-infected individuals. Int J STD AIDS (1996) 1.39